TFF Pharmaceuticals, Inc. announced that data from the Company?s ongoing Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) for the prevention of lung transplant rejection is available on the Company?s website. These data were recently presented by Professor Gregory Snell, the lead Principal Investigator of the TFF TAC Phase 2 study, via an oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 44th Annual Meeting during a late breaking clinical science abstract session on April 13, 2024. The data became available following the Company?s 8-K filing.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.21 USD | 0.00% | -3.49% | -68.52% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-68.52% | 6.85M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+42.21% | 40.47B | |
-10.02% | 27.17B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- TFFP Stock
- News TFF Pharmaceuticals, Inc.
- TFF Pharmaceuticals, Inc. Makes Available Phase 2 Data from Tacrolimus Inhalation Powder for Prevention of Lung Transplant Rejection Presented at Recent ISHLT Annual Meeting